Scientists have systematically investigated oxazolidinone analogues for activity against the bacterium Mycobacterium tuberculosis. These analogs show limited inhibition of mitochondrial protein synthesis. They identified several compounds suitable for safe once-daily dosing. The lead molecule is effective in mouse models of tuberculosis. This molecule is safe in four month toxicity studies. A low toxicity analog of linezolid has potential for use in all patients with tuberculosis. The article was published in Nature Medicine on January 15, 2026.